Tally Health is a technology company.
Tally Health has raised $10.0M across 1 funding round.
Tally Health has raised $10.0M in total across 1 funding round.
Tally Health has raised $10.0M in total across 1 funding round.
Tally Health's investors include Forerunner Ventures, Lightspeed Venture Partners, Owl Ventures, Red Swan Ventures, sequel, Gwyneth Paltrow, John Legend, Kevin Hart, Michael G. Rubin, Ryan Duranso, Steve Aoki.
# Tally Health: High-Level Overview
Tally Health is a consumer biotechnology company focused on epigenetic aging and longevity science[2]. The company develops tools and personalized interventions designed to help users understand and slow their biological aging process. Rather than treating age-related diseases individually, Tally positions aging itself as a treatable medical condition and offers members a comprehensive system combining epigenetic testing, personalized action plans, and science-backed longevity supplements[2].
The company serves health-conscious consumers interested in preventive wellness and longevity. Its core offering addresses a fundamental problem: while genetics account for less than 10% of how people age, over 90% is determined by lifestyle choices and environment[2]. Tally empowers users to optimize this controllable portion through data-driven insights and targeted interventions. Since its commercial launch in February 2023, the company has demonstrated significant traction—62% of members reduced their epigenetic age by an average of 2.34 years, while 75% improved their lifestyle survey scores across diet, fitness, sleep, mental health, and habits[3].
# Origin Story
Tally Health was co-founded by Dr. David Sinclair, a globally renowned longevity scientist[2]. The company emerged from decades of clinical research in aging science, with the founding team's mission to translate cutting-edge longevity breakthroughs into accessible consumer tools[2]. The company launched commercially in February 2023[3], positioning itself at the intersection of consumer health technology and epigenetic science—a relatively nascent market segment focused on biological age measurement and reversal.
# Core Differentiators
# Role in the Broader Tech Landscape
Tally Health operates within the rapidly expanding longevity biotechnology sector, riding several converging trends. First, consumer interest in preventive health and biohacking has accelerated, with individuals increasingly willing to invest in tools that provide biological insights[2]. Second, advances in epigenetic science have made biological age measurement feasible at scale, moving longevity from theoretical research into practical application[3]. Third, the shift toward personalized medicine—where interventions are tailored to individual genetics and lifestyle—aligns with broader healthcare transformation away from one-size-fits-all treatments[1].
The company's emphasis on making longevity science "accessible" reflects a market opportunity: most longevity research remains confined to academic institutions and wealthy individuals. By democratizing epigenetic testing and science-backed supplements, Tally influences how the broader consumer health ecosystem thinks about aging as a preventable condition rather than an inevitable decline[2].
# Quick Take & Future Outlook
Tally Health is positioned to expand significantly as consumer demand for longevity solutions grows and epigenetic testing becomes more mainstream. The company's stated goals include expanding research and development, integrating TallyAge feedback into digital experiences, and expanding internationally beyond the United States[2]. Success will depend on maintaining scientific credibility while scaling operations, demonstrating sustained member outcomes, and navigating regulatory frameworks around health claims.
The company represents a broader shift in how technology addresses aging—moving from reactive treatment of age-related diseases toward proactive, data-driven optimization of the aging process itself. As the longevity market matures, Tally's combination of rigorous science, proprietary technology, and consumer accessibility positions it as a potential category leader in making biological age reversal a mainstream health practice.
Tally Health has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Seed in April 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2023 | $10.0M Seed | Forerunner Ventures, Lightspeed Venture Partners, Owl Ventures, Red Swan Ventures, sequel, Gwyneth Paltrow, John Legend, Kevin Hart, Michael G. Rubin, Ryan Duranso, Steve Aoki |